retatrutide triple agonist gip glp-1 glucagon phase 3 2025 ๐จ Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. ๐ Mean body weight change at 80 weeks: โฌ๏ธ Retatrutide in Obesity and Diabetes
Pay in 4 interest-free payments of $6.74 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 17 - Aug 22






:max_bytes(150000):strip_icc()/VWH-GettyImages-1469751146-5eff6dd0b38449ff9dca9313c7c393d5.jpg)





:max_bytes(150000):strip_icc()/VWH-GettyImages-2275860768-a6f6e63304e048d0a829844c1dacbd8d.jpg)















